During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the ...
-- Blueprint Medicines will receive $775 million in upfront payments, comprising $675 million in cash and $100 million equity investment priced at $96.57 per share, and is eligible to receive up to ...
Reni Benjamin, an analyst from JMP Securities, reiterated the Buy rating on Blueprint Medicines (BPMC – Research Report). The associated price target remains the same with $125.00. Discover ...
Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...
The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline. Paul Hudson, CEO of Sanofi said, "The proposed acquisition of Blueprint Medicines ...
On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
CAMBRIDGE, Mass., March 3, 2015 -- Blueprint Medicines today announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed activated ...
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' (BPMC) leadership role in advancing care for patients with systemic mastocytosis -- "Our ...
Blueprint Medicines drug reduces mastocytosis symptoms in a new study, meeting investor expectations
A drug made by Blueprint Medicines markedly improved symptoms of a rare immune system disorder called non-advanced systemic mastocytosis in a clinical trial that is being closely watched by investors, ...
It looks like this biotech has what big-pharma companies have been eager to acquire. Blueprint Medicine's stock made its biggest leap of the year thanks to data from the Navigator trial in patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback